Healthcare Industry News: Medline
News Release - February 6, 2008
Misonix Announces New Distribution Strategy for SonicOne(TM) Ultrasonic Wound Debridement SystemFARMINGDALE, N.Y.--(HSMN NewsFeed)--Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology for the ablation of cancer and other chronic health conditions, today announced that its agreement with Medline Industries, Inc., Mundelein, IL, for the domestic distribution of the SonicOne™ Ultrasonic Wound Debridement System has expired. In a limited release test market, Misonix and Medline have been working together to determine the best distribution model for the product. Both parties now believe that the best opportunity for market success would be sales of the product by Misonix through a proprietary distribution network. Medline will continue to close pending SonicOne™ sales opportunities through March of this year.
The response to the SonicOne™ product has been very positive. To date, the SonicOne has been used by over 50 physicians in more than 2,500 debridement procedures.
David G. Armstrong, DPM, PhD, has thoroughly investigated the clinical use of the SonicOne™ Ultrasonic Wound Debridement System and has gained substantial experience with the device. He is Professor of Surgery and Associate Dean at the Rosalind Franklin University of Medicine and Science, Chicago, IL, and is an active participant in the assessment and development of wound healing systems. His study areas include development and evaluation of cutting-edge treatments designed to heal wounds and prevent amputation in high risk populations.
“Few can argue the importance of routine serial debridement as a central tenet of wound healing and amputation prevention. My team and I have significant clinical experience with the SonicOne™ System, which has proven to be an important adjunct to primary and maintenance debridement in our unit,” said Dr. Armstrong. “We use it routinely for treating acute and chronic wounds like diabetic foot and pressure ulcers, arterial and venous ulcers, colonized bacterial wounds, burns, or dehisced ulcers. The SonicOne™ has become a valuable tool in our practice.”
The SonicOne’s precision, its stimulating effect on the microenvironment of the wound and its efficient eradication of bio-film make it a highly useful tool. Imploding cavitation bubbles create micro flow patterns within the irrigation stream and break away necrotic cells from viable tissue, thus contributing to thorough and selective debridement. Preservation of healthy tissue leads to granulation of the wound bed with reduced bleeding and less tissue trauma compared to debridement with sharp instruments. Related pain has been reported as reduced and well tolerated, even in hyper-sensitive patients.
According to Michael A. McManus, Jr., President and CEO of Misonix, “We have enjoyed our relationship with Medline and appreciate their assistance during this test market period. Both companies were very pleased with the acceptance of the SonicOne™ by the medical community. We, at Misonix, have been looking for an opportunity to more directly interface with our clinical customers. The SonicOne™ will be the start of proprietary distribution for Misonix products in the domestic market. We already distribute our Sonastar™ Surgical Aspiration System through a growing distribution network in Europe and Latin America. We will leverage our growing product portfolio to promote new distribution relationships in the U.S. and expand our present international agreements to increase sales and create added value for our shareholders.”
Misonix, Inc. (NASDAQ: MSON ) designs, develops, manufactures, and markets, therapeutic ultrasonic medical devices, and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissue without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with intentional tasks and currency fluctuation, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.